The FDA program is designed to prioritize access to experimental drugs for patients with grave or life-threatening medical issues. And while the name of the individual is not known, several signs indicate that they are likely very well connected. A senior clinician at the National Institutes of Health, Ranganath Muniyappa, requested access to the drug […]
Read More